ADVM Company Profile and Key Details

Adverum Biotechnologies, Inc. generated EPS of -$8.57 over the past year. Five-year average earnings growth is 8.03%. The latest quarter delivered EPS of -$2.03. The next quarter is forecast at -$1.63. Next year's EPS is expected at $27.84. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $33.00 to $4.00. The high target offers 656.88% upside. The low target suggests -8.26% downside. The mean target is $16.80. This offers 285.32% upside. Adverum Biotechnologies, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 12.78%. The prior quarter beat by 4.46%. Over the last six quarters, Apple has recorded several small beats. These include -29.92% in August 12, 2024.

ADVM has shown sold momentum, gaining 4.81% over the past week and 31.72% over the past quarter, though year-to-date performance is down -6.64%. Short-term trend indicators are mixed aligned (SMA20 3.35%, SMA50 -1.22%, SMA200 25.49%). The stock’s 14-day RSI is 58.2 (neutral), while the ATR of 0.13 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -28.76% below its high and over 144.94% above its low.

Adverum Biotechnologies, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.63. This means the shares are trading below this model’s fair value.

Adverum Biotechnologies, Inc. has 22.08 million shares outstanding. The public float is 17.76 million shares, elevated short interest at 4.16% of float. This equals 811.40 thousand shares. The short ratio is 0.93 days. Institutional investors hold 77.62% of the float. Insiders own 13.04%. Leonard Braden Michael holds 1.96 million shares, Blumenkranz Mark S. has 522.99 thousand shares and Schwartz Steven Daniel has 367.93 thousand shares. Over the past six months, insider transactions show net selling. They sold 1.10 million shares across 4 transactions.

The stock is currently mid-range between its 52-week high and low $1.78 and $6.07. With a market capitalization of about $96.26 million, Adverum Biotechnologies, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.87). Key stats such as the average daily volume over the past year has been around 724.34 thousand shares, in line with its 52-week average. Headquartered in Redwood City, CA, Adverum Biotechnologies, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Laurent Fischer, the company employs approximately 155 people and listed since July 31, 2014. Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases.

Adverum Biotechnologies, Inc. trades at a P/E ratio of -0.5, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -1.84 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.7, also below market averages.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) shares are flat -6.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Adverum Biotechnologies, Inc. trading at a premium to the broader market with a P/E of -0.5. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $17.19, suggesting 294.27% upside. Our AI forecast model points to short-term strength (0.23% over two weeks), a medium-term rise (32.8% over three months), and a longer-term gain (142.2% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Adverum Biotechnologies, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.23%, with price expected at $4.37 by December 23, 2025, within a range of $4.29 to $4.45 3-Month Outlook: Projected rise of 32.8%, reaching $5.79 by March 09, 2026, with a range of $5.55 to $6.04. 1-Year Outlook: Projected gain of 142.2%, with price at $10.56 by December 09, 2026, within a range of $0.00 to $16.24.